NDI warning letters fuel criticism of FDA enforcement approach Regulation of Dietary Supplements and Other Specialized Categories The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Issues Warning Letters Against Online GLP 1 Sellers BioSpace FTC and U.S. FDA Warning Letter re: Products Containing CBD October 22, 2019